Myostatin: a potential therapeutic target for metabolic syndrome
Metabolic syndrome is a complex metabolic disorder, its main clinical manifestations are obesity, hyperglycemia, hypertension and hyperlipidemia. Although metabolic syndrome has been the focus of research in recent decades, it has been proposed that the occurrence and development of metabolic syndro...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1181913/full |
| _version_ | 1797822011915894784 |
|---|---|
| author | Ming Yang Ming Yang Chongbin Liu Chongbin Liu Na Jiang Na Jiang Yan Liu Yan Liu Shilu Luo Shilu Luo Chenrui Li Chenrui Li Hao Zhao Hao Zhao Yachun Han Yachun Han Wei Chen Wei Chen Li Li Li Li Li Xiao Li Xiao Lin Sun Lin Sun |
| author_facet | Ming Yang Ming Yang Chongbin Liu Chongbin Liu Na Jiang Na Jiang Yan Liu Yan Liu Shilu Luo Shilu Luo Chenrui Li Chenrui Li Hao Zhao Hao Zhao Yachun Han Yachun Han Wei Chen Wei Chen Li Li Li Li Li Xiao Li Xiao Lin Sun Lin Sun |
| author_sort | Ming Yang |
| collection | DOAJ |
| description | Metabolic syndrome is a complex metabolic disorder, its main clinical manifestations are obesity, hyperglycemia, hypertension and hyperlipidemia. Although metabolic syndrome has been the focus of research in recent decades, it has been proposed that the occurrence and development of metabolic syndrome is related to pathophysiological processes such as insulin resistance, adipose tissue dysfunction and chronic inflammation, but there is still a lack of favorable clinical prevention and treatment measures for metabolic syndrome. Multiple studies have shown that myostatin (MSTN), a member of the TGF-β family, is involved in the development and development of obesity, hyperlipidemia, diabetes, and hypertension (clinical manifestations of metabolic syndrome), and thus may be a potential therapeutic target for metabolic syndrome. In this review, we describe the transcriptional regulation and receptor binding pathway of MSTN, then introduce the role of MSTN in regulating mitochondrial function and autophagy, review the research progress of MSTN in metabolic syndrome. Finally summarize some MSTN inhibitors under clinical trial and proposed the use of MSTN inhibitor as a potential target for the treatment of metabolic syndrome. |
| first_indexed | 2024-03-13T10:01:34Z |
| format | Article |
| id | doaj.art-ba79638c60c041b3a5d77758c40e4b27 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-13T10:01:34Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-ba79638c60c041b3a5d77758c40e4b272023-05-23T05:30:55ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-05-011410.3389/fendo.2023.11819131181913Myostatin: a potential therapeutic target for metabolic syndromeMing Yang0Ming Yang1Chongbin Liu2Chongbin Liu3Na Jiang4Na Jiang5Yan Liu6Yan Liu7Shilu Luo8Shilu Luo9Chenrui Li10Chenrui Li11Hao Zhao12Hao Zhao13Yachun Han14Yachun Han15Wei Chen16Wei Chen17Li Li18Li Li19Li Xiao20Li Xiao21Lin Sun22Lin Sun23Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, ChinaHunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, ChinaMetabolic syndrome is a complex metabolic disorder, its main clinical manifestations are obesity, hyperglycemia, hypertension and hyperlipidemia. Although metabolic syndrome has been the focus of research in recent decades, it has been proposed that the occurrence and development of metabolic syndrome is related to pathophysiological processes such as insulin resistance, adipose tissue dysfunction and chronic inflammation, but there is still a lack of favorable clinical prevention and treatment measures for metabolic syndrome. Multiple studies have shown that myostatin (MSTN), a member of the TGF-β family, is involved in the development and development of obesity, hyperlipidemia, diabetes, and hypertension (clinical manifestations of metabolic syndrome), and thus may be a potential therapeutic target for metabolic syndrome. In this review, we describe the transcriptional regulation and receptor binding pathway of MSTN, then introduce the role of MSTN in regulating mitochondrial function and autophagy, review the research progress of MSTN in metabolic syndrome. Finally summarize some MSTN inhibitors under clinical trial and proposed the use of MSTN inhibitor as a potential target for the treatment of metabolic syndrome.https://www.frontiersin.org/articles/10.3389/fendo.2023.1181913/fullmyostatinmetabolic syndromeobesitydiabeteslipid |
| spellingShingle | Ming Yang Ming Yang Chongbin Liu Chongbin Liu Na Jiang Na Jiang Yan Liu Yan Liu Shilu Luo Shilu Luo Chenrui Li Chenrui Li Hao Zhao Hao Zhao Yachun Han Yachun Han Wei Chen Wei Chen Li Li Li Li Li Xiao Li Xiao Lin Sun Lin Sun Myostatin: a potential therapeutic target for metabolic syndrome Frontiers in Endocrinology myostatin metabolic syndrome obesity diabetes lipid |
| title | Myostatin: a potential therapeutic target for metabolic syndrome |
| title_full | Myostatin: a potential therapeutic target for metabolic syndrome |
| title_fullStr | Myostatin: a potential therapeutic target for metabolic syndrome |
| title_full_unstemmed | Myostatin: a potential therapeutic target for metabolic syndrome |
| title_short | Myostatin: a potential therapeutic target for metabolic syndrome |
| title_sort | myostatin a potential therapeutic target for metabolic syndrome |
| topic | myostatin metabolic syndrome obesity diabetes lipid |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1181913/full |
| work_keys_str_mv | AT mingyang myostatinapotentialtherapeutictargetformetabolicsyndrome AT mingyang myostatinapotentialtherapeutictargetformetabolicsyndrome AT chongbinliu myostatinapotentialtherapeutictargetformetabolicsyndrome AT chongbinliu myostatinapotentialtherapeutictargetformetabolicsyndrome AT najiang myostatinapotentialtherapeutictargetformetabolicsyndrome AT najiang myostatinapotentialtherapeutictargetformetabolicsyndrome AT yanliu myostatinapotentialtherapeutictargetformetabolicsyndrome AT yanliu myostatinapotentialtherapeutictargetformetabolicsyndrome AT shiluluo myostatinapotentialtherapeutictargetformetabolicsyndrome AT shiluluo myostatinapotentialtherapeutictargetformetabolicsyndrome AT chenruili myostatinapotentialtherapeutictargetformetabolicsyndrome AT chenruili myostatinapotentialtherapeutictargetformetabolicsyndrome AT haozhao myostatinapotentialtherapeutictargetformetabolicsyndrome AT haozhao myostatinapotentialtherapeutictargetformetabolicsyndrome AT yachunhan myostatinapotentialtherapeutictargetformetabolicsyndrome AT yachunhan myostatinapotentialtherapeutictargetformetabolicsyndrome AT weichen myostatinapotentialtherapeutictargetformetabolicsyndrome AT weichen myostatinapotentialtherapeutictargetformetabolicsyndrome AT lili myostatinapotentialtherapeutictargetformetabolicsyndrome AT lili myostatinapotentialtherapeutictargetformetabolicsyndrome AT lixiao myostatinapotentialtherapeutictargetformetabolicsyndrome AT lixiao myostatinapotentialtherapeutictargetformetabolicsyndrome AT linsun myostatinapotentialtherapeutictargetformetabolicsyndrome AT linsun myostatinapotentialtherapeutictargetformetabolicsyndrome |